Protocol for a Prospective, Single-arm, Multicenter Clinical Study on the Efficacy and Safety of Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors
Latest Information Update: 14 Jan 2026
At a glance
- Drugs Iruplinalkib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 14 Jan 2026 New trial record